Eye banking: an introduction by Rao, Gullapalli N & Gopinathan, Usha
46 COMMUnIty EyE HEaLtH JOURnaL | VOL 22 ISSUE 71 | DECEMBER 2009
EYE BANKING
Eye banking: an introduction
While prevention is the most desirable way 
to control corneal blindness, once a cornea 
has lost its transparency, a corneal trans-
plant, or graft, is a patient’s best chance to 
regain vision in the affected eye(s). 
However, the biggest limiting factor is the 
worldwide shortage of donated corneas. 
In low- and middle-income countries, 
where the magnitude of corneal blindness is 
greatest, the availability of donated corneas 
is very low. This is due in large part to the 
lack of local eye banks. Efforts are under 
way to develop eye banks of optimal 
standards in many low- and middle-income 
countries, with countries like India and 
Philippines making notable progress. 
Myanmar, Ethiopia (see box right), and Kenya 
are examples where high quality eye banks 
have been established. However, this is still 
not enough to meet the need for corneas. 
What is an eye bank?
Eye banks are the institutions responsible 
for collecting (harvesting) and processing 
donor corneas, and for distributing them to 
trained corneal graft surgeons.1 Eye banks 
are regulated and part of the local health 
system; they may be attached to a hospital 
or housed in a separate building.
Cornea harvesting is the surgical removal 
from a deceased person of either the whole 
eye (enucleation) or the cornea (in situ 
corneal excision). This can be done by 
appropriately trained eye care personnel 
(eye bank technicians, ophthalmology 
residents, ophthalmologists, or general 
practitioners) in a variety of settings, including 
hospitals, homes, and funeral grounds.
Before harvesting
Corneas can be harvested up to twelve 
hours after death, but ideally within six 
hours. The person who will harvest the 
cornea must first do the following:
• Obtain written consent from the senior 
next of kin of the deceased.
• Verify the death certificate and ensure 
there is a stated cause of death.
• Review the donor’s medical and social 
history to ensure they have no contra-
indications to donation. (This is done by 
studying medical records, interviewing the 
physician under whose care the donor 
was, and interviewing close family members. 
Each eye bank must have a list of such 
contraindications, which are available 
from other well-established eye banks.)
• Obtain information about any blood loss 
occurred prior to and at time of death, and 
whether the donor received infusion/
transfusion of crystalloids, colloids, and 
blood; these are used to calculate 
plasma dilution.
During harvesting
Aseptic methods must be adhered to, including 
maintaining a sterile field while performing 
enucleation or in-situ corneal excision.2 
Standard protocols include:
• pen torch examination of the eyes for 
foreign objects and other defects
• preparing the face and eyes of the donor 
using povidone iodine
• employing aseptic techniques for in situ 
corneal excision or enucleation
• immediate preservation of the excised eye 
or cornea in an appropriate cornea 
preservation medium
• drawing blood to screen the donor for 
infectious diseases. Each eye bank must 
decide the most appropriate serological 
tests needed but at a minimum they must 
test for HIV, hepatits B, and syphilis.
Storing donated corneas
Whole eyes can be stored in a moist 
chamber at two to eight degrees Celsius. 
This is the simplest and least expensive way 
to store whole eyes, but the eyes have to be 
used within 48 hours. Such a storage 
method may be suitable for some eye banks 
with limited resources. 
Excised corneas can be stored in inter-
mediate-term preservation media, such as 
McCary Kaufman medium (MK medium) or 
Optisol, both maintained at four degrees 
Celsius. Corneas can be stored for 96 hours 
in the MK medium and ten days in Optisol. 
With the availability of MK medium and 
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The Eye Bank of Ethiopia in Addis Ababa has been in existence since 2003. It is associated 
with Menelik II Referral Hospital, a tertiary referral centre, where most of the transplants are 
done. The eye bank also sends corneas to two university referral hospitals in northwestern 
and southern Ethiopia. Between 130 and 150 corneas are harvested (using in situ corneal 
excision) and used in 90–120 transplants every year. 
There are five corneal transplant surgeons in 
Ethiopia. Cornea donation is encouraged in a variety 
of ways, including media campaigns with well-known 
personalities such as the president of Ethiopia and 
athlete Haile Gabreselassi. So far, 6,000 Ethiopians, 
including Mr Gabreselassi, have pledged their 
corneas, and next-of-kin consent is being used 
increasingly. The eye bank is funded by ORBIS 
International Ethiopia and Addis Ababa City 
Government Health Bureau; it also raises funds 
locally. (Elmien Wolvaardt Ellison)
The Eye Bank of Ethiopia
a technician at work in the Eye 
Eye Bank of Ethiopia
a group of children 
on a visit to the Eye 
Bank of Ethiopia
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Dear Editor,
It was with great sadness that we learnt of 
the death of Prof Barrie Jones on 19 
August 2009 in Tauranga, New Zealand, 
aged 88.
He was admired worldwide for his work in 
developing the concept of prevention of 
blindness and for establishing the 
International Centre for Eye Health 
(publishers of the Community Eye Health 
Journal) in 1981. He was in fact responsible 
for encouraging the launch of the first issues 
of this journal. However, your readers may 
not be aware of his major contributions, 
earlier in his career as first clinical professor 
of ophthalmology in the University of 
London, to the science and management of 
corneal and external eye disease.
Barrie first addressed the range of virus 
infections of the eye seen in London, writing 
about adenovirus infection and corneal 
involvement by the vaccinia virus. He 
conducted much laboratory research on 
herpes simplex infection, and randomised 
trials of interferon, idoxuridine, trifluorothy-
midine, adenine arabinoside, and ultimately 
acyclovir. A rational approach was developed 
to the management of different stages of 
herpetic keratitis, including mechanical 
debridement, when to use corticosteroids, 
and the role of corneal grafting.1
Although a much less common cause of 
keratitis than in tropical countries, fungi 
nonetheless caused serious corneal infec-
tions in London. Barrie and his colleagues 
cultivated and tested the sensitivity of every 
fungus isolate to many different potential 
new drugs. He emphasized that the varia-
tions in sensitivity within each species were 
so great that it was necessary to base 
rational therapy on the results of sensitivity 
testing of each patient’s own fungus.2
Barrie Jones was widely known as an 
authority on many aspects of trachoma. He 
developed methods of isolation, culture, 
and laboratory diagnosis. In extensive field 
studies in Tunisia, Iraq, and Iran he eluci-
dated the seasonal dynamics of 
transmission of blinding hyperendemic 
trachoma, recognising the importance of 
multicyclic re-infection and the role of flies 
in transmission in these countries. He 
carried out trials of early potential vaccines 
and of chemotherapy.3
He investigated and wrote about an 
astonishing range of other corneal condi-
tions, including infections by amoebae, 
vernal and other allergic types of keratocon-
juntivitis, Thygeson’s superficial punctate 
keratitis, pemphigoid, and dry eye 
syndromes. In the operating theatre, he 
pioneered new surgery of the lacrimal 
canaliculi and duct and improved the 
techniques, postoperative management, 
and outcomes of corneal grafting. 
When, around 1980, he turned the full 
energy of his thinking to the questions of 
blindness prevention, it was informed by this 
rich background of laboratory and clinical 
experience.
Gordon Johnson
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Optisol, eye banks should ideally switch over 
from enucleation to in situ corneal excision 
procedures. This will enable better viability 
of donated corneas during storage. With 
increased resistance to the antibiotics used 
in preservation media, inclusion of alter-
native antibiotics must be considered.3
After corneas reach the eye bank, they 
are examined using a slit lamp to check for 
corneal and stromal pathology. The 
endothelial cell density is also examined by 
specular microscope; this is necessary as 
donor corneas with a low number of 
endothelial cells are likely to fail soon after 
surgery. The processing of whole eyes must 
be done within a laminar flow hood 
maintained in sterile conditions. 
The suitability of a cornea for transplan-
tation is assessed by the corneal surgeon, 
who will consider the donor screening report, 
slit lamp and specular microscopic results, 
and serology reports. Following processing 
and evaluation of corneas and serological 
testing, transplantable corneas are trans-
ported to hospitals individually sealed and 
packaged, maintaining the cold chain at four 
degrees Celcius. The vial containing the 
cornea must be labelled properly with the 
eye bank name, tissue number, name of the 
preservative medium, medium lot number, 
expiry date of the medium, and date and 
time of the donor’s death. The surgeon must 
also be provided with the donor screening, 
tissue evaluation, and serology reports. It is 
important that the eye bank follows a fair 
and equitable system of tissue distribution. 
Standards
Eye banks should develop and adhere to 
acceptable standards. This reduces the risk 
that grafts will fail or that infection will be 
transmitted. It may help to refer to the technical 
guidelines and acceptable minimum medical 
standards of the European Eye Banking 
Association (see Useful Resources, page 38).
Finding donors
Even with an effective eye bank, finding 
enough people willing to donate their 
corneas can be difficult. 
Public awareness programmes play an 
important role. They must emphasise that 
corneas can be donated by anyone, 
whatever their age, religion, or gender, and 
that neither enucleation nor in situ corneal 
excision causes disfigurement of the face or 
any delays in funeral arrangements. Family 
pledging is also becoming more important 
as family consent is usually needed before 
eyes or corneas can be removed. 
Some of these problems may be circum-
vented by favourable legislation for eye 
donation, such as a ‘required request’ law. 
This law requires hospital authorities to 
identify potential cornea donors and obtain 
consent from bereaved family members. 
Another law employed in some countries, 
such as the United States and Ethiopia, is a 
‘presumed consent’ law. Under this law, 
every person who dies while in hospital is 
presumed to be an eye donor unless this is 
actively rejected by their next of kin.
Hospital cornea retrieval programmes 
can meet some of the immediate need. In 
these programmes, trained eye donation 
counsellors approach family members of 
the deceased and motivate them to 
consider eye donation. Training these 
counsellors in the art of grief counselling 
assists them in approaching family members 
at an appropriate time, sharing their grief, 
and preparing them to take the positive step 
of giving permission for eye donation on 
behalf of their loved one. 
References
1  Rao GN. What is eye banking? Indian J Ophthalmol 
1996;44: 1–2.
2  Mannis MJ, Reinhart WJ. Medical standards for eye 
banks. In Brightbill F (ed): Corneal surgery, theory, 
technique and tissue, pp 531–548. St Louis: CV 
Mosby, 1993.
3  Gopinathan U, Agarwal V, Sharma S, Rao GN. Donor 
corneoscleral rim contamination by gentamicin resistant 
organisms. Indian J Ophthalmol 1994;42: 71–74.
Barrie Jones, after his retirement, discussing 
the progress of the clinical trial of ivermectin 
with Prof adenike abiose. nIGERIa
an eye donation counsellor speaks to family 
members of a deceased person. InDIa
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